SCHEMBL3377569

SCHEMBL3377569

CS(=O)(=O)Nc1ccc(-c2ccc(Cl)c(C(F)(F)F)c2)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 6/20 0.51
SCN9A Q15858 1/20 0.50
CYP17A1 P05093 3/20 0.47
NOTUM Q6P988 1/20 0.46
MAPT P10636 2/20 0.46
NR3C1 P04150 1/20 0.45
AR P10275 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.44
EPHX2 P34913 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
TP53 P04637 1/20 0.44
KDR P35968 1/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378774 0.90 KIF11 (0.55) KIF11SCN9ACYP17A1NR3C1AR
SCHEMBL15218451 0.86 KDR (0.57) KIF11CYP17A1MAPTKMT2AEPHX2
SCHEMBL3375971 0.84 KIF11 (0.66) KIF11GAAHPGDMAPK1EPHX2
SCHEMBL3376954 0.82 KIF11 (0.48) KIF11SCN9ACYP17A1NR3C1AR
SCHEMBL3375785 0.82 KIF11 (0.59) KIF11SCN9ACYP17A1MAPTNR3C1
SCHEMBL3375693 0.81 KIF11 (0.54) KIF11CYP17A1GAAHPGDMAPK1
SCHEMBL3375688 0.81 KIF11 (0.56) KIF11SCN9AMAPTGAAHPGD
SCHEMBL3374747 0.80 KIF11 (0.51) KIF11CYP17A1MAPTNR3C1AR
SCHEMBL3377083 0.80 PTGS2 (0.52) KIF11CYP17A1MAPTGAAHPGD
SCHEMBL3378764 0.79 PTGS2 (0.51) KIF11CYP17A1MAPTNR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIF11 3561/4885SCN9A 70/4885CYP17A1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.